Uncategorized

Less than two months after splitting from Illumina, the liquid biopsy maker is refocusing resources as it pursues an FDA submission for the Galleri multi-cancer early detection test.

Intended to supplement medications, the six-week, app-based treatment will cost $50 on a cash-pay basis.

New information is emerging about the joint care delivery platform first teased earlier this spring, which is launching without Elevance’s assets.

The FDA said Globus delayed reporting complaints about misplaced screws, despite information that “reasonably suggests” the Excelsius GPS system malfunctioned.

The layoffs will help extend the company’s cash runway from the second half of 2026 into 2028.

The documents released Tuesday say Prospect is under federal investigation for possible False Claim Act violations, and faces state investigations for failing to safeguard patient data before a ransomware attack last year.

More than 80% of denied requests were overturned when appealed, but few beneficiaries formally questioned the decisions.

The new Medicare prices for the first 10 drugs negotiated under the Inflation Reduction Act are expected soon. Analysts and researchers are divided on the long-term effects of the law.

The European Union has approved the first-ever combination therapy consisting of an immunotherapy and a PARP inhibitor for the treatment of endometrial cancer, AstraZeneca announced Wednesday.

Rivus Pharmaceuticals will push HU6 into Phase III development and is looking to engage with regulatory authorities and launch a late-stage study next year in obesity-related heart failure with preserved ejection fraction.